微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 59.84% | 9.37% | 10.32% | 50/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 54.24% | 6.75% | -0.84% | 71/159 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 54.71% | 9.18% | 1.13% | 67/159 | 22.98% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 54.1% | 6.3% | -1.13% | 70/159 | 33.39% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 54.72% | 8.24% | 7.68% | 65/159 | 51.73% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 50.81% | -3.4% | 1.41% | 76/159 | 51.53% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 50.11% | -4.49% | -1.54% | 78/159 | 32.76% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 50.89% | -0.88% | 0.68% | 76/159 | 38.65% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 50.55% | -1.48% | -3.9% | 77/159 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 52.6% | 1.97% | 0.26% | 81/159 | 53.74% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 52.46% | 4.67% | 2.18% | 75/159 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 51.34% | 2.51% | 0.06% | 81/159 | 21.74% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 51.31% | -0.25% | -0.54% | 77/159 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 51.59% | 11.35% | 2.92% | 81/159 | 55.21% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 50.12% | 4.38% | 0.08% | 74/159 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 50.09% | 3.69% | -2.63% | 80/159 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 51.44% | 8.77% | 11.03% | 71/159 | 54.21% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 46.33% | -1.17% | -3.53% | 91/159 | -144.37% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 48.02% | 4.43% | -0.58% | 74/159 | 56.57% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 48.3% | 1.08% | 2.14% | 80/159 | 54.32% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 47.29% | -3.78% | 0.88% | 70/159 | 55.5% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 46.88% | 1.06% | 1.94% | 85/159 | -1213.38% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 45.98% | -4.73% | -3.77% | 67/159 | 55.47% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 47.79% | 7.03% | -2.77% | 68/159 | 55.47% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 49.15% | 16.37% | 5.95% | 60/159 | 51.37% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 46.38% | -19.64% | -3.9% | 79/159 | -205.91% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 48.27% | -18.84% | 8.1% | 59/159 | 54.25% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 44.65% | -33.16% | 5.72% | 65/159 | 53.68% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 42.23% | 2% | -26.83% | 67/159 | 54.19% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 57.72% | -7.26% | -2.94% | 49/159 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 59.47% | 2% | -10.98% | 31/159 | 49.32% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 66.8% | 8.86% | 7.33% | 20/159 | 48.02% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 62.24% | -1.8% | 1.43% | 30/159 | 48.44% | 退市金泰 | 95.93% | 行业排名> |
| 2016-06-30 | 61.36% | 2% | -3.18% | 26/159 | 46.2% | 贝达药业 | 95.58% | 行业排名> |
| 2015-12-31 | 63.38% | 2% | 2% | 22/159 | 46.24% | 贝达药业 | 95.89% | 行业排名> |